Impact of the first nirsevimab immunization campaign on RSV-related emergency department visits and hospitalizations in Québec, Canada

Read the full article

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Objectives

During the 2024-2025 respiratory syncytial virus (RSV) season, a universal nirsevimab infant immunization program was implemented in the province of Québec. We evaluated its population-level impact on RSV-related emergency department (ED) visits and hospitalizations in infants, using both active surveillance and administrative health data.

Methods

Study population included all Québec children <18 years old. Incidence rates of RSV-confirmed hospitalizations (6 hospital-based active surveillance), RSV-associated hospitalizations and ED visits linked to a positive RSV test, and acute bronchiolitis ED visits (administrative databases) were measured for nirsevimab-eligible (0-5 months old) and non-eligible (6-11 months and 1-17 years old) age groups during the 2024-2025 season and compared to the previous seasons (varying lookback periods). Using difference-in-differences and observed versus expected approaches, pre-/post-intervention variations in 0-5-month-olds were adjusted for any time trends extending to non-targeted age groups.

Results

Decreases of 59% (95% CI: 49–70) and 66% (95% CI: 58–71) were observed in RSV-confirmed and RSV-associated hospitalizations, respectively. Acute bronchiolitis ED visits decreased by 35% (95% CI: 28–41), and RSV-associated ED visits, by 60% (95% CI: 56–65). This impact became noticeable approximately one week after expanding the campaign to all eligible infants. ED visits and hospitalizations were less frequent than expected (i.e. without nirsevimab) in 0-5-month-olds, across all indicators. Between 323 and 746 hospitalizations were possibly prevented.

Conclusion

The 2024-2025 nirsevimab campaign was associated with a two-thirds reduction in RSV-related hospitalizations and RSV-associated ED visits in Québec infants. ED visits for acute bronchiolitis were also reduced by a third.

Article activity feed